# EDGAR Filing Document

**Accession Number:** 0001426800
**File Stem:** 0001123292-25-000353
**Filing Date:** 2025-8
**Character Count:** 12689
**Document Hash:** 18de2545b0892165e954d5f724d6fd65
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001123292-25-000353.hdr.sgml**: 20250812

**ACCESSION NUMBER**: 0001123292-25-000353

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250812

**DATE AS OF CHANGE**: 20250812

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASSEMBLY BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001426800
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-85836
- **FILM NUMBER:** 251207185

**BUSINESS ADDRESS:**
- **STREET 1:** TWO TOWER PLACE
- **STREET 2:** 7TH FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (833) 409-4583

**MAIL ADDRESS:**
- **STREET 1:** TWO TOWER PLACE
- **STREET 2:** 7TH FLOOR
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VENTRUS BIOSCIENCES INC
- **DATE OF NAME CHANGE:** 20080211
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GILEAD SCIENCES, INC.
- **CENTRAL INDEX KEY:** 0000882095
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 943047598
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 6505743000

**MAIL ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GILEAD SCIENCES INC
- **DATE OF NAME CHANGE:** 19930328

## Exhibit 99.1

#### Exhibit 99
The name and present principal occupation of each of the executive officers and directors of Gilead Sciences, Inc. are set forth below. Unless otherwise noted, each of these persons have as their business address c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404.

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Title** | **Citizenship** | **Principal Occupation and, if not employed by Gilead Sciences, Inc., Name, Principal Business and<br> Address of Employer** |
| Daniel P. O'Day | Chief Executive Officer, Chairman and Director | United States | \* |
| Jacqueline K. Barton, Ph.D. | Director | United States | Professor Emerita, California Institute of Technology |
| Jeffrey A. Bluestone, Ph.D. | Director | United States | President and Chief Executive Officer, Sonoma Biotherapeutics |
| Sandra J. Horning, M.D. | Director | United States | Retired Chief Medical Officer, Roche Inc. |
| Kelly A. Kramer | Director | United States | Retired Executive Vice President and Chief Financial Officer, Cisco Systems, Inc. |
| Ted W. Love, M.D. | Director | United States | Chair of Board of Directors, Biotechnology Innovation Organization |
| Harish Manwani | Director | Singapore | Senior Operating Partner, Blackstone |
| Javier J. Rodriguez | Director | Mexico | Chief Executive Officer, DaVita, Inc. |
| Anthony Welters | Director | United States | Lead Independent Director; Chairman and Chief Executive Officer, CINQ Care |
| Andrew D. Dickinson | Chief Financial Officer | United States | \* |
| Johanna Mercier | Chief Commercial Officer | United States | \* |
| Dietmar Berger, M.D., Ph.D. | Chief Medical Officer | United States | \* |
| Deborah H. Telman | Executive Vice President, Corporate Affairs and General Counsel | United States | \* |

---

\* The present principal occupation for each of these individuals is officer of Gilead Sciences, Inc. and officer, trustee and/or director of other affiliated entities.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**ASSEMBLY BIOSCIENCES, INC.**

*(Name of Issuer)*

**Common Stock, par value $0.001**

*(Title of Class of Securities)*

**045396108**

*(CUSIP Number)*

**Gilead Sciences, Inc.**<br>333 Lakeside Drive<br>Foster City CA 94404<br>650-574-3000

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**08/08/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **045396108** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**GILEAD SCIENCES, INC.** | Name of reporting person<br>**GILEAD SCIENCES, INC.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**4505391.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**4505391.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**4505391.00** | Aggregate amount beneficially owned by each reporting person<br>**4505391.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**29%** | Percent of class represented by amount in Row (11)<br>**29%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** Comment relating to row 13: Based upon 15,560,009 shares of Common Stock of the Issuer issued and outstanding upon the closing of the Issuer's most recent public offering, which was completed on August 11, 2025, as disclosed in the prospectus supplement (the "Prospectus Supplement") filed with the Securities and Exchange Commission (the "SEC") on August 11, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001

**(b) Name of Issuer:**
ASSEMBLY BIOSCIENCES, INC.

**(c) Address of Issuer's Principal Executive Offices:**
Two Tower Place, 7th Floor, South San Francisco, CA, 94080

This Amendment No. 3 ("Amendment No. 3") amends and supplements the Schedule 13D filed by the Reporting Person with the SEC on October 25, 2023, as amended by Amendment No. 1 filed with the SEC on June 20, 2024 and Amendment No. 2 filed with the SEC on December 23, 2024 (as amended by Amendment No. 2, the "Schedule 13D"), which relates to the Common Stock of the Issuer. Unless otherwise indicated, all capitalized terms used herein shall have the meanings set forth in the Schedule 13D and, unless amended hereby, all information previously disclosed remains unchanged.

**Item 4. Purpose of Transaction**

Item 4 is amended to add the following immediately following the last paragraph:
 
2025 Securities Purchase Agreement and Warrants

On August 8, 2025, pursuant to the 2025 Purchase Agreement, Gilead purchased from the Issuer 2,295,920 shares of Common Stock, the Series A Warrant, and the Series B Warrant, at a combined purchase price of $19.60 per share of Common Stock and accompanying one half of one Series A Warrant and one half of one Series B Warrant. 

The Series A Warrant is exercisable, in whole or in part, immediately at an exercise price of $21.60 per share and expires on the earlier of (i) 5:00 p.m. (New York City time) on August 11, 2030 and (ii) the date that is 30 days after the public announcement (whether by press release, document filed or furnished with the SEC, or other form of public announcement) that the Issuer has completed enrollment (of at least 200 patients total) for its Phase 2 clinical study evaluating ABI-5366 vs. valacyclovir.

The Series B Warrant is exercisable, in whole or in part, on or after November 15, 2026 at an exercise price of $21.60 per share and expires on December 31, 2026, provided that the Series B Warrant will automatically terminate in full and be extinguished and shall no longer be exercisable in the event that the Issuer publicly announces prior to November 15, 2026 that it has received at least $75.0 million in the aggregate of non-dilutive capital in connection with a collaboration agreement.

Each of the Series A Warrant and the Series B Warrant cannot be exercised by Gilead if, after giving effect thereto, Gilead would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the Issuer's outstanding shares of Common Stock, subject to certain exceptions.

The foregoing descriptions of the 2025 Purchase Agreement, the Series A Warrant, and the Series B Warrant are not complete and are subject to and qualified in their entirety by reference to the full text of such documents, which are attached as Exhibits 99.2, 99.3, and 99.4 hereto and incorporated herein by reference.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Item 5(a) of the Schedule 13D is hereby amended and restated to read as follows:

Number of shares beneficially owned: Gilead Sciences, Inc. - 4,505,391 Shares
Percent of class: Gilead Sciences, Inc. - 29.0%

The percent ownership was calculated based upon 15,560,009 shares of Common Stock of the Issuer issued and outstanding upon the closing of the Issuer's most recent public offering, which was completed on August 11, 2025, as disclosed in the Prospectus Supplement.

**(b)**
Item 5(b) of the Schedule 13D is hereby amended and restated to read as follows:

(i) Sole power to vote or to direct the vote: Gilead Sciences, Inc. - 4,505,391 shares
(ii) Shared power to vote or to direct the vote: Gilead Sciences, Inc. - 0 shares
(iii) Sole power to dispose or to direct the disposition of: Gilead Sciences, Inc. - 4,505,391 shares
(iv) Shared power to dispose or to direct the disposition of: Gilead Sciences, Inc. - 0 shares

To the best knowledge of the Reporting Person, none of the individuals listed on Exhibit 99.1 beneficially owns any of the Issuer's Common Stock.
 
The Reporting Person beneficially owns a warrant to purchase 179,500 shares of Common Stock (the "2024 Warrant") that was acquired from the Issuer on June 17, 2024, the Series A Warrant, and the Series B Warrant (collectively, the "Warrants"). Each of the Warrants is subject to a limitation pursuant to which the Reporting Persons may not exercise such Warrant if such exercise would cause the Reporting Person to beneficially own Common Stock in an amount exceeding the "Beneficial Ownership Limitation" (as defined in such Warrant) then in effect. The Beneficial Ownership Limitation with respect to each Warrant is subject to adjustment upon 61 days' notice by the holder of such Warrant to the Issuer and, as of the date of this Amendment No. 3, was 19.99% of the number of shares of Common Stock outstanding. As a result, none of the aggregate of 2,475,420 shares of Common Stock underlying the Warrants are deemed to be beneficially owned by the Reporting Persons.

**(c)**
Item 5(c) of the Schedule 13D is hereby amended and restated to read as follows:

Except as reported in this Amendment No. 3, neither the Reporting Person nor, to the best knowledge of the Reporting Person, any of the individuals listed on Exhibit 99.1 have effected any transactions in the Common Stock during the past sixty (60) days.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** GILEAD SCIENCES, INC.

**Signature:** /s/ Andrew D. Dickinson

**Name/Title:** Andrew D. Dickinson, Chief Financial Officer

**Date:** 08/12/2025